Xbridge beh c18

Manufactured by Waters Corporation

Sourced in United States

The XBridge BEH C18 is a high-performance liquid chromatography (HPLC) column designed for a wide range of analytical applications. It features a hybrid organic/inorganic bonded phase that provides stability and efficient separation of diverse analytes.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

XBridge C18 (505 citations) BEH C18 (162 citations) XBridge BEH C18 column (87 citations) XBridge Peptide BEH C18 column (53 citations) XBridge Peptide BEH C18 (12 citations) XBridge™ BEH 130 C18 (10 citations) XBridge BEH C18 OBD Prep Column (9 citations) XBridge BEH C18 XP (6 citations) XBridge BEH C18 XP Column (5 citations) XBridge BEH C18 OBD (5 citations)

36 protocols using xbridge beh c18

High-pH Reverse-Phase Peptide Fractionation

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The samples (n = 44) were reconstituted in 400 μL of 1.0 mol/L triethylammonium bicarbonate at pH 7.5 and injected into the chromatography system. Tryptic peptides were fractionated at high pH reverse-phase XBridge BEH C18 analytical column (250 mm × 4.6 mm, 130 °A, 5 μm, Waters Corporation, Milford, Massachusetts) equipped with an XBridge BEH C18 sentry guard cartridge. The separation was achieved at a flow rate of 0.5 μL/min in 10 mmol/L triethylammonium bicarbonate and water at pH 7.5 (solvent A) and 100% acetonitrile (solvent B). A multistep gradient with three linear gradients were used; from 0 to 5% (solvent) B in 10 minutes, 5% to 35% B in 60 minutes, 35% to 60% B in 15 minutes, and 70% B for 10 minutes before reaching the initial conditions. A total of 60 fractions were collected and recombined into 15 peptide fractions as previously described.^{10 (link)} The samples were evaporated to dryness in a Speed-Vac concentrator and stored in −80 °C until LC MS/MS runs.

Sharpnack M.F., Ranbaduge N., Srivastava A., Cerciello F., Codreanu S.G., Liebler D.C., Mascaux C., Miles W.O., Morris R., McDermott J.E., Sharpnack J.L., Amann J., Maher C.A., Machiraju R., Wysocki V.H., Govindan R., Mallick P., Coombes K.R., Huang K, & Carbone D.P. (2018). Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13(10), 1519-1529.

+ Open protocol

+ Expand

Sensitive Peptide Identification by Orbitrap MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peptides (0.375 μg) were injected on a trap column (40 × 0.1 mm, XBridge BEHC18, 5 μm; Waters, Milford, MA), desalted for 5 min at a flow of 4 μL/min, separated on a pulled-tip analytical column (150 × 0.075 mm, XBridge BEHC18, 3.5 μm; Waters), and heated to 50°C with a three-segment linear gradient of acetonitrile, 0.1% FA (B) in water, and 0.1% FA (A) as follows: 0–3 min 1–7% B, 3–53 min 7–25% B, 53–60 min 25–35% B, and then 80% B and re-equilibration at 0.4 μL/min (nanoACQUITY UPLC; Waters). Tandem mass spectrometry (MS/MS) spectra were acquired on Orbitrap Fusion (Thermo Fisher Scientific, Waltham, MA) operated in data-dependent mode with higher-energy collisional dissociation fragmentation (normalized collisional energy 25%) and MS/MS acquisition. MS spectra were acquired at resolution 60,000 and MS/MS spectra (MS/MS selection window 2 Da) at resolution 15,000. Peptides and proteins were identified using the Comet search engine, with PeptideProphet and ProteinProphet validation (20 ppm tolerance window for precursors and products, Cys alkylation and methionine oxidation as fixed and variable modifications, respectively).

Vaisar T., Durbin-Johnson B., Whitlock K., Babenko I., Mehrotra R., Rocke D.M, & Afkarian M. (2018). Urine Complement Proteins and the Risk of Kidney Disease Progression and Mortality in Type 2 Diabetes. Diabetes Care, 41(11), 2361-2369.

+ Open protocol

+ Expand

Comparative Peptide Separation Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Identical chromatographic conditions were used to allow direct comparison of the three MS methods. Following desalting on a C18 trap (Waters XBridge BEH C18, 5 μm, 0.075 × 40 mm), peptides were separated using an in house packed C18 column (Waters XBridge BEH C18, 3.5 μm, 0.075 × 100 mm) with an integrated electrospray emitter pulled using a laser micropipette puller (Sutter Instrument, Novato, CA). The column was kept at 50 °C. A nanoACQUITY UPLC (Waters, Milford, MA) was used for the separation with a linear gradient of solvents A and B (0.1% formic acid in water; solvent B −0.1% formic acid in acetonitrile). Peptide digest (0.25 μg) were injected onto the trap column at a flow of 3 μL/min of 99% solvent A. After 6 minutes the valve was switched, and the peptides were eluted from the trap column onto the analytical column at a flow rate of 0.6 μL/min. A multi-step gradient was applied as follows: linear 1 to 7% solvent B in 3 minutes, a linear gradient increasing solvent B from 7 to 25% in 16 minutes, followed by an increase from 25 to 35% B in 3 minutes. The column was subsequently washed for 3 minutes at 80% B and re-equilibrated at 99% A for 11 minutes.

Ronsein G.E., Pamir N., von Haller P.D., Kim D.S., Oda M.N., Jarvik G.P., Vaisar T, & Heinecke J.W. (2014). Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. Journal of proteomics, 0, 388-399.

+ Open protocol

+ Expand

Offline Peptide Fractionation for Proteome and Methylome Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

100 μg peptides (for proteome analysis) or 15 mg peptides (for methylome analysis) were off-line fractionated by bRP (basic Reverse Phase) using a Waters XBridge BEH C18 5 μm 4.6 × 250 mm column (Waters) or XBridge BEH C18 10 μm 10 × 250 mm column (Waters) on an Ultimate 3000 high-pressure liquid chromatography (HPLC) system (Dionex, Sunnyvale, CA, USA) operating at 1 mL/min or 2.5 mL/min. Buffer A (5 mM ammonium formate, pH 10) and buffer B (5 mM ammonium formate, pH 10, 90% (v/v) ACN) were adjusted to pH 10 with ammonium hydroxide. Peptides were separated by a linear gradient from 5% B to 35% B in 54 mins followed by a linear increase to 70% B in 6 mins. A total of 60 fractions were collected. For comprehensive proteomic analysis, the 60 fractions were concatenated to 20. For comprehensive methylome analysis, the 60 fractions were concatenated to 10. All the concentrated fractions were lyophilized.

Peng B.L., Li W.J., Ding J.C., He Y.H., Ran T., Xie B.L., Wang Z.R., Shen H.F., Xiao R.Q., Gao W.W., Ye T.Y., Gao X, & Liu W. (2020). A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis. Theranostics, 10(8), 3451-3473.

+ Open protocol

+ Expand

Quantification of Fluticasone Propionate by LC-MS/MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

Liquid chromatography for fluticasone propionate was accomplished using a Shimadzu LC-20AD liquid chromatograph with an XBridge BEH C18 (2.5 μm 2.1 × 50 mm) analytical column (Waters) protected with a guard column. The mobile phase consisted of 0.1% ammonium hydroxide (mobile A) and methanol (mobile phase B), and used a gradient of 50% to 95% mobile phase B over 1.5 min. The flow rate was 0.3 mL/min and the total run time was 5 min. Compounds were detected using a Thermo TSQ Ultra triple quadrupole mass spectrometer equipped with a heated electrospray ionization source in the positive ion mode. The spray voltage was held at 4.0 kV and the vaporizer temperature at 300 °C. Fluticasone propionate and d₅ fluticasone propionate (internal standard) were detected by multiple-reaction monitoring (MRM) using the transitions 501 ≥ 293 m/z and 506 ≥ 293 m/z, respectively. Calibration curves were fit using linear regression with 1/X² weighting in Xcalibur^® v. 2.0 (Thermo Fisher Scientific, Waltham, MA, USA).

Prasher A., Shrivastava R., Dahl D., Sharma-Huynh P., Maturavongsadit P., Pridgen T., Schorzman A., Zamboni W., Ban J., Blikslager A., Dellon E.S, & Benhabbour S.R. (2021). Steroid Eluting Esophageal-Targeted Drug Delivery Devices for Treatment of Eosinophilic Esophagitis. Polymers, 13(4), 557.

+ Open protocol

+ Expand

Quinoline-3-carboxylic Acid Amide Synthesis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 85

[Figure (not displayed)]

To a solution of 6-methoxy-8-[4-(trifluoromethyl)phenoxy]quinoline-3-carboxylic acid (20 mg, 55 umol, 1 eq), propan-2-amine (3.9 mg, 66 umol, 5.68 uL, 1.2 eq) and DIPEA (7.1 mg, 55 umol, 1 eq) in DCM (1 mL) was added HATU (25.1 mg, 66 umol, 1.2 eq). The reaction mixture was stirred at 25° C. for 1 hr. LC-MS showed starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (5 mL) and the resultant mixture was extracted with EA (20 mL*3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*25 mm*5 um; mobile phase: [water (0.04% NH₃H₂O 10 mM NH₄HCO₃)-ACN]; B %: 50%-80%, 7.8 min) to give the title compound as a white solid. LCMS (ESI): RT=0.911 min, mass calcd for C₂H₁₉F₃N₂O₃404.13 m/z, found 405.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.03 (d, J=2.3 Hz, 1H), 8.54 (d, J=2.0 Hz, 1H), 7.62 (d, J=8.5 Hz, 2H), 7.16 (d, J=8.5 Hz, 2H), 6.98 (d, J=2.5 Hz, 1H), 6.93 (d, J=2.5 Hz, 1H), 6.08 (br d, J=6.8 Hz, 1H), 4.37 (qd, J=6.7, 13.8 Hz, 1H), 3.93 (s, 3H), 1.33 (d, J=6.5 Hz, 6H).

US11384049B2. Bicyclic compounds (2022-07-12). Vivace Therapeutics, Inc. [US]. Inventors: Andrei W. Konradi [US], Tracy Tzu-Ling Tang Lin [US].

+ Open protocol

+ Expand

Synthesis of a Quinoline-based Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 87

[Figure (not displayed)]

To a solution of 6-methoxy-8-[4-(trifluoromethyl)phenoxy]quinoline-3-carboxylic acid (20 mg, 55 umol, 1 eq), (2R)-2-aminopropan-1-ol (4.9 mg, 66 umol, 1.2 eq) and DIPEA (7.1 mg, 55 umol, 1 eq) in DCM (1 mL) was added HATU (25.1 mg, 66 umol, 1.2 eq). The reaction mixture was stirred at 25° C. for 1 hr. LC-MS showed starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (5 mL) and the resultant mixture was extracted with EA (20 mL*3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*25 mm*5 um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B %: 40%-70%, 9 min) to give the title compound (9.27 mg, 39% yield) as a white solid. LCMS (ESI): RT=0.840 min, mass calcd for C₂H₁₉F₃N₂O₄420.13 m/z, found 421.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.07 (d, J=2.0 Hz, 1H), 8.55 (d, J=2.0 Hz, 1H), 7.62 (d, J=8.5 Hz, 2H), 7.16 (d, J=8.5 Hz, 2H), 6.97 (d, J=2.5 Hz, 1H), 6.93 (d, J=2.5 Hz, 1H), 6.60 (br d, J=7.5 Hz, 1H), 4.44-4.32 (m, 1H), 3.93 (s, 3H), 3.86 (dd, J=3.5, 11.0 Hz, 1H), 3.71 (dd, J=5.5, 11.0 Hz, 1H), 1.35 (d, J=6.8 Hz, 3H).

US11420935B2. Bicyclic compounds (2022-08-23). Vivace Therapeutics, Inc. [US]. Inventors: Andrei W. Konradi [US], Tracy Tzu-Ling Tang Lin [US].

+ Open protocol

+ Expand

Analytical and Semi-preparative HPLC Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

Analytical chromatography was performed on a Waters Alliance e2695 system, equipped with a 2998 PDA detector. The columns used were Waters XBridge BEH C18 4.6 mm × 50 mm, 2.5 μm or Waters Symmetry C18 4.6 mm × 250 mm, 3.5 μm. Solvent A was water, solvent B acetonitrile, and solvent C water containing 1% of trifluoroacetic acid. The Waters XBridge column was used under gradient conditions as follows: flow rate, 1.5 mL/min; column temperature, 40°C; t=0 min 80% A/10% B/10% C; t=5 min 0% A/90% B/10% C; t= 6 min 0%A/100% B/0% C; run time 8 min; UV detection from 200 to 800 nm. The Waters Symmetry column was used under isocratic conditions as follows: flow rate 1.5 mL/min; column temperature, 35°C; t=0 min 35% A/55% B/10% C.
Semi-preparative chromatography was performed on a Waters Autopurification system composed of a Binary Gradient Module 2545 pump, a 996 PDA detector and a 2767 Sample Manager. Solvent A was water with 0.1% TFA, solvent B acetonitrile with 0.1% TFA. The column used was a Waters XBridge OBD C18 10 mm × 100 mm, 5 μm and the conditions were as follows: t=0 min 55% A/ 45%B; t= 5 min 55% A/45%B; t= 5.5 min 50% A/50% B; t=12 min 50% A/50% B; t=12.5 min 45%A/55%B; t=17 min 45% A/55%B; t=19 min 0% A/100% B; run time 25 min; UV detection from 200 to 800 nm.

Poncelet M., Driesschaert B., Bobko A.A, & Khramtsov V.V. (2017). Triarylmethyl-based biradical as a superoxide probe. Free radical research, 52(3), 373-379.

+ Open protocol

+ Expand

HPLC-UV Optimization for Ibuprofen Detection

Check if the same lab product or an alternative is used in the 5 most similar protocols

An HPLC-UV system was optimized for the detection of IBU prior to the analysis. The liquid chromatography system used was a quaternary pump (Agilent, Santa Clara, CA, USA) with an autosampler and Xbridge BEH C18, 3.5 μm, 2.1 × 50 mm, Waters column. The column temperature was 50 °C and injector temperature was 20 °C. The Mobile phase A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in acetonitrile. The flow rate was 0.800 mL/min. The injector wash was 50% acetonitrile. The retention time was 4.45 min, and the run time was 8.0 min. UV Detection at the wavelength of 220 nm was used. The IBU stock solution was prepared in the biorelevant medium at 250 ug/mL and used for the calibration curve at 1:250 v/v. Calibration samples were run prior to the analysis of the studied samples.

Mantas A., Labbe V., Loryan I, & Mihranyan A. (2019). Amorphisation of Free Acid Ibuprofen and Other Profens in Mixtures with Nanocellulose: Dry Powder Formulation Strategy for Enhanced Solubility. Pharmaceutics, 11(2), 68.

+ Open protocol

+ Expand

Ketamine-loaded Polymeric Microparticle Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Accurately weighed amounts (~10 mg; n = 3) of the ketamine-loaded polymeric microparticles (Table 1) were dissolved in acetonitrile. The ketamine concentrations were quantified using HPLC (Agilent 1200 series) with UV detection at 280 nm. A gradient HPLC method was used for determining the drug loading (DL) using a Waters XBridge BEH C18 column: 3.5 µm, 3.0 × 150 mm. The calibration range was 5–800 µg/mL. The mean (±SD) correlation coefficients for ketamine calibration curves were 0.9998 (±0.0001).
Drug incorporation efficiency, expressed as actual drug loading (% w/w), and encapsulation efficiency (EE % w/w) were calculated using Equations (1) and (2), respectively. The individual values for three replicate determinations and their mean values are reported.

Han F.Y., Whittaker A.K., Howdle S.M., Naylor A., Shabir-Ahmed A., Zhang C, & Smith M.T. (2018). Formulation of Bioerodible Ketamine Microparticles as an Analgesic Adjuvant Treatment Produced by Supercritical Fluid Polymer Encapsulation. Pharmaceutics, 10(4), 264.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!